EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Evotec SE's enterprise value is €1,714.8 Mil.
Evotec SE's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was €-65.1 Mil. Therefore, Evotec SE's EV-to-EBITDA for today is -26.33.
The historical rank and industry rank for Evotec SE's EV-to-EBITDA or its related term are showing as below:
WBO:EVT'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -423.41 Med: 31.83 Max: 560.38
Current: -26.33
During the past 13 years, the highest EV-to-EBITDA of Evotec SE was 560.38. The lowest was -423.41. And the median was 31.83.
WBO:EVT's EV-to-EBITDA is ranked worse than 100% of 708
companies
in the Drug Manufacturers industry
Industry Median: 14.375
vs WBO:EVT: -26.33
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-04-30), Evotec SE's stock price is €9.44.
Evotec SE's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.390. Therefore, Evotec SE's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Evotec SE EV-to-EBITDA Historical Data
The historical data trend for Evotec SE's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Evotec SE's EV-to-EBITDA
For the Drug Manufacturers - Specialty & Generic subindustry, Evotec SE's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Evotec SE's EV-to-EBITDA Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Evotec SE's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Evotec SE's EV-to-EBITDA falls into.
Evotec SE EV-to-EBITDA Calculation
Evotec SE's EV-to-EBITDA for today is calculated as:
Evotec SE's current Enterprise Value is €1,714.8 Mil.
Evotec SE's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-65.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Evotec SE (WBO:EVT) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Evotec SE's share price for today is €9.44.
Evotec SE's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.390.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Evotec SE's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Evotec SE is a drug discovery partnership company providing solutions to pharmaceutical & biotechnology companies, academic institutions as well as foundations, and not-for-profit organizations. The company offers its services in the area of neuronal diseases, diabetes & its complications, pain, inflammation, oncology, infectious diseases, respiratory & fibrosis, rare disease, and women's health. Its business segments are EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone drug discovery services on a typical fee-for-service basis or integrated drug discovery collaborations. The EVT Innovate segment develops drug discovery programs and assets, both internally and through academic collaborations. The majority of its revenue is derived from the EVT Execute segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
WBO:EVT has been successfully added to your 